E icosapentaenoic acid (EPA) and other dietary n-3 fatty acids have been associated with improved cardiovascular health. 1 In the current issue, Nakajima et al demonstrate that diet-supplemented EPA leads to the regression of atherosclerotic lesions in the murine Ldlr Ϫ/Ϫ model. 2 They provide evidence that regression is mediated through the induction of indoleamine 2,3-dioxygenase (IDO) and the downregulation of costimulatory molecules by dendritic cells (DCs), leading to a reduced abundance and activation of T lymphocytes. These data offer new mechanistic insights to the role of EPA in improving atherosclerotic disease.
See accompanying article on page 1963
An important role for acquired immunity has been established in experimental murine models of severe hypercholesterolemia. 3 On one hand, the development of atherosclerotic lesions is enhanced by CD4 ϩ T-cells and Th1 cytokines, and on the other hand regulatory T-cells confer protection against atherogenesis. DCs are important gate-keepers of acquired immunity, primarily because of their ability to activate CD4 ϩ T-cells in a highly efficient manner. This likely occurs primarily in secondary lymphoid tissues, even under conditions of hypercholesterolemia. 4 The fact that DCs are found in close proximity to T-cells in human advanced atherosclerotic lesions 5 suggests that they may also activate T-cells locally.
Ingested essential polyunsaturated fatty acids are metabolized to biologically active lipid mediators. 1 Generally, proinflammatory lipid mediators are derived from linoleic acid and arachidonic acid (n-6 fatty acids) and include the classic eicosanoids responsible for inflammation (prostaglandins, prostacyclins, thromboxanes, and leukotrienes). Under conditions that promote the resolution of inflammation, arachidonic acid undergoes a "lipid-mediator class switch" and is metabolized into antiinflammatory eicosanoids called lipoxins. Concurrently, ␣-linolenic acid metabolites EPA and docosahexaenoic acid are converted into other antiinflammatory lipid mediators including the resolvins, protectins, and maresins. 6, 7 These n-3 fatty acid-derived mediators and their associated metabolites are proresolving and generally much less proinflammatory than their n-6 counterparts. Thus, it may be desirable to increase the consumption of n-3 fatty acids that are especially enriched in oily fish and marine mammals. The American Heart Association recommends that patients with documented coronary heart disease intake 1 g/day of EPA and docosahexaenoic acid. 8 DCs can regulate T-cell effector responses through several pathways. This includes induction of regulatory T-cells, regulation of T-cell activation and modulation of T-cell proliferation and apoptosis. Expression of ligands of inhibitory receptors such as programmed death-1 can dampen T-cell activation. Reduced proliferation or apoptosis can be accomplished through the lack of costimulation, and/or production of arginase and IDO enzymes that catabolize amino acids required for T-cell proliferation, including arginine and tryptophan, respectively. 9 There are several proposed mechanisms by which n-3 fatty acids may mediate DC functions. In vitro treatment with EPA or its major metabolite resolvin E1 led to the decreased synthesis of proinflammatory cytokines such as IL-12 by DCs and the induction of T-cell apoptosis by DCs. 10 -12 Previous studies demonstrated beneficial effects of n-3 fatty acids in experimental atherogenesis. Feeding atherosclerotic Apoe Ϫ/Ϫ mice ␣-linolenic acid reduced lesion size and T-cell infiltration; however, there was no detectable change in T-cell-or DC-specific expression of costimulatory molecules. 13 EPA administration regressed lesions in Apoe Ϫ/Ϫ mice and downregulated endothelial cell expression of adhesion molecules including VCAM-1 and ICAM-1, leading the authors to postulate that this was through the induction of PPAR␣ expression in macrophages and reduced NF-B activation. 12 In another study of obesity-related atherosclerosis, feeding ob/ob; Ldlr Ϫ/Ϫ mice EPA regressed lesions and restored the ability of plaque macrophages to appropriately clear apoptotic cells. 14 In this issue of ATVB, Nakajima et al provide additional insights into other potential mechanisms of EPA-mediated cardioprotection. 2 Ldlr Ϫ/Ϫ mice were placed on a high-cholesterol diet to establish atherosclerotic lesions. Switching to a regular chow diet for 4 weeks lowered serum cholesterol levels and halted lesion progression, whereas regular chow together with EPA administration reduced pre-established lesion size by approximately 25%. EPA reduced serum cholesterol levels beyond those of the regular chow (non-EPA-treated) group, yet adjustment of the diet to normalize serum cholesterol levels provided evidence that lesion regression was not secondary to greater reduction of lipid levels, but attributable to EPA. Regressed lesions contained less CD11c ϩ DCs, MOMA-2 ϩ macrophages and CD4 ϩ T-cells, with a corresponding increase in smooth muscle cell and collagen content, which are features of plaque stability. Importantly, EPA reduced the expression of costimulatory molecules on the DC surface, both in lesions and in the secondary lymphoid tissues. DCs isolated from secondary lymphoid organs of EPA-fed mice had decreased expression of maturation markers, an increased expression of IDO, a cytokine profile skewed toward an antiinflammatory response, and an impaired ability to induce T-cell proliferation.
CD4 ϩ T-cell levels were reduced in secondary lymphoid organs of EPA-treated mice, but numbers of CD25 ϩ FoxP3 ϩ regulatory T-cells were comparable. EPA did not affect CD4 ϩ T-cell apoptosis, proliferation in response to a direct proliferative stimulus, or cytokine production, consistent with its primary role as a modulator of DC function (Figure) . EPA-mediated plaque regression was dependent on IDO activity, as inhibition of IDO function resulted in comparable lesions to the regular chow group.
The results from this animal study reflect some recent clinical findings. A study from Finland found increased expression of IDO in atherosclerotic plaques, along with a corresponding increase in coinhibitory molecules such as CTLA4 and ICOS. 15 Another recent study randomized the treatment of 2 patient cohorts awaiting carotid endarterectomy with capsules containing EPA or control oil. 16 After surgical removal of the carotid plaque, the EPA-treated group demonstrated preferential incorporation of EPA in these plaques and a reduced number of foam cells.
Furthermore in the EPA-treated patient group, plaque EPA content had an inverse relationship with plaque instability score, number of T-cells, and mRNA expression of proinflammatory cytokines and matrix metalloproteinases. In summary, the study by Nakajima et al provides compelling mechanistic information on how EPA contributes to the regression of atherosclerotic lesions in mice, by impairing the ability of DCs to activate T-cells in an IDO-dependent manner. This study has important implications for the management of atherosclerosis and may impact other T-cellmediated inflammatory diseases. 
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